Pending NDAs To Be Poussot’s Top Priority As Wyeth’s Upcoming CEO

Upon assuming the role of Wyeth President and CEO in January, Bernard Poussot will make his top priority the approval of the seven applications pending FDA review decisions, Poussot said during the firm's third quarter earnings call Oct. 18